Vectus Biosystems Ltd
VBS
Company Profile
Business description
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including cardio, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
Contact
26-34 Dunning Avenue
Unit 5, Ground Floor
Rosebery
SydneyNSW2018
AUST: +61 283441300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,212.70 | 61.50 | -0.66% |
| CAC 40 | 8,361.36 | 28.49 | 0.34% |
| DAX 40 | 26,771.88 | 109.11 | 0.41% |
| Dow JONES (US) | 52,297.09 | 189.40 | -0.36% |
| FTSE 100 | 10,863.09 | 27.62 | 0.25% |
| HKSE | 23,801.71 | 206.84 | -0.86% |
| NASDAQ | 25,366.09 | 100.10 | -0.39% |
| Nikkei 225 | 61,816.72 | 997.36 | 1.64% |
| NZX 50 Index | 14,181.31 | 77.92 | -0.55% |
| S&P 500 | 7,592.40 | 26.98 | -0.35% |
| S&P/ASX 200 | 9,089.00 | 57.80 | -0.63% |
| SSE Composite Index | 3,660.09 | 4.26 | 0.12% |